financetom
Business
financetom
/
Business
/
Measures by Colombia stock exchange may allow it to stay in JPMorgan index -president
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Measures by Colombia stock exchange may allow it to stay in JPMorgan index -president
Apr 29, 2024 7:19 AM

BOGOTA, April 29 (Reuters) - Measures adopted by the

Colombian stock exchange and securities issuers to improve

liquidity could be enough for the country to hold onto its

"emerging market" classification and stay in a key JPMorgan ( JPM )

index, but more progress is needed, the stock exchange's

president said.

Last year JPMorgan ( JPM ) warned Colombia could be excluded from

its MSCI emerging markets index and be downgraded to a frontier

market due to declining liquidity.

The warning sparked a sharp drop in share prices across the

stock exchange as a downgrade would drive away foreign investors

guided by the bank's indexes.

Just three Colombian stocks are included in JPMorgan's ( JPM ) MSCI

index; Bancolombia, Bancolombia Preferential and energy

conglomerate ISA.

The stock exchange has cut costs for issuing new shares,

while companies have hired liquidity providers to promote them,

among other measures, in a combined effort to boost liquidity,

Colombian stock exchange chief executive Andres Restrepo said.

"From our figures, we don't think the downgrade risk will

materialize," Restrepo told Reuters late on Friday. "The

performance of the three stocks that form part of the MSCI

Emerging index has recovered."

In March, Davivienda, Colombia's third-largest bank, carried

out a share issue for $183.4 million, while Spanish bank BBVA's

Colombian unit said in mid-April that it was preparing a share

issue worth 220 million euros.

The next step will be to promote including other companies

into JPMorgan's ( JPM ) MSCI emerging markets index, which will require

more share issues, said Restrepo, who has held the job since

February.

Cementos Argos could be a candidate following a

decision to convert its preferential shares into common shares,

Restrepo said, adding that Colombia's majority state-owned oil

company Ecopetrol could return to the index after it

was pushed out at the end of 2022.

"Ecopetrol could very quickly enter the index with a

decision I understand is no small thing, but which is to

increase its float by selling no more than 3% (of its shares),"

Restrepo said.

Currently, 11.5% of Ecopetrol's shares are traded on the

stock market, while 88.5% is owned by the Colombian state.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved